In November 2017, we participated in the United Nations Global Compact (U...
We have been donating and providing research grants to public interest in...
Our Stance on Supply Chain Management Joining the PSCI (Pharmaceutical...
DE&I Initiatives (Promotion of diverse human resources) Other Init...
Efforts made to promote employees’ health Organizational structure to ...
ONO has established a medium- to long-term environmental challenge vision...
Basic Policy Examples of Innovative pharmaceutical products R & D ...
In the evaluation on climate change conducted by the CDP, a global e...
Governance We recognize the preservation of the global environment as ...
In 2023, ONO PHARMA KOREA became a vigorous supporter of the childhood...
Sustainability Report 2023 Sustainability Report 2023 Susta...
Please refer to the “Corporate Governance Report” below for details on ou...
At Ono Pharmaceutical, the Board of Directors oversees important manageme...
We implement all the principles of the Corporate Governance Code stipulat...
When newly appointing third parties, such as contractors or agents, we co...
Since the misconduct that occurred in FY2020 (hereinafter referred to as ...
Sites where data were collected: [Non-consolidated] Fujiyama Plan...
Corporate Governance Structure Corporate Governance Code Corporate...
Related SDGs Activities ...
